Despite considerable progress, most antibody recruiters reported to date suffer from a fundamental weakness: they rely on monovalent interactions at both ends. The small haptens commonly used to bind endogenous antibodies have intrinsically low affinity, and the dense sugar coating on tumor cell membranes, the glycocalyx, further shields these interactions from working efficiently. Polymeric antibody-recruiting systems have been developed to present multiple binding motifs at once, boosting avidity, but they often sacrifice control over how the motifs are spatially arranged and which cells they engage. Nonspecific membrane anchoring and synthetic polymer scaffolds raise additional concerns about off-target effects and biocompatibility, leaving open a central design question: how can small molecules generate a cell-selective, multivalent antibody-binding display without permanent, bulky synthetic scaffolds?

A team reporting in Advanced Science has now answered that question with a strategy borrowed from supramolecular chemistry: receptor-triggered peptide self-assembly. Their approach exploits a principle that biology itself uses everywhere, in which many weak interactions acting in concert become collectively strong. The researchers designed a series of modular peptide conjugates, labeled P1 through P4, each combining three functional modules. The first is GE11, a twelve-amino-acid peptide (sequence YHWYGYTPQNVI) that binds the epidermal growth factor receptor, EGFR, which is overexpressed on many aggressive tumors. The second is dinitrophenyl, or DNP, a classic hapten recognized by anti-DNP antibodies that can be raised or already present in serum. The third is a short self-assembly motif built from diphenylalanine, a dipeptide famous for its tendency to form ordered beta-sheet nanostructures. Polyethylene glycol linkers of varying lengths were inserted to tune solubility and flexibility, and P4, which lacks the diphenylalanine motif, served as a non-assembling control.

The design logic is elegant. In solution, the conjugates exist as discrete monomers. Once the GE11 module docks onto EGFR on a cancer cell membrane, however, the receptor acts as a nucleating scaffold that guides the diphenylalanine motifs to polymerize in situ into extended fibrillar networks. The result is a dense, spatially confined carpet of DNP haptens displayed directly on the tumor cell surface, precisely where they are needed to capture anti-DNP antibodies with high avidity. Transmission electron microscopy confirmed the transformation: P3 alone formed mostly amorphous aggregates, but when incubated with EGFR protein it assembled into extended fibrillar networks, while the control peptide P4 formed no ordered structures under identical conditions. The assembly proved robust across physiologically relevant buffer and pH conditions tested.

The quantitative gains from assembly were striking. On EGFR-overexpressing HeLa cells, P3, which carries a PEG6 spacer identified as the optimal balance between hapten accessibility and receptor anchoring, recruited anti-DNP antibodies with normalized mean fluorescence intensities 4.6-fold and 9.4-fold higher than P4 at concentrations of 10 and 20 micromolar respectively after three hours. Time-course experiments showed recruitment rising rapidly within the first three hours and plateauing by 24 hours, reaching an 11.8-fold advantage over the non-assembling control. Assembly also conferred a survival benefit to the molecule itself: in serum stability assays containing 30 percent fetal bovine serum, P3 retained roughly 28 percent of its initial concentration after eight hours, whereas P4 was completely degraded. The critical aggregation concentration of P3 was measured at 6.5 micromolar, and microscale thermophoresis confirmed that supramolecular modification did not compromise receptor binding, with P3 retaining high affinity for EGFR comparable to the parental GE11 ligand.

Selectivity, the property that determines whether such a therapy can spare healthy tissue, was verified at multiple levels. Competitive experiments showed that free GE11 markedly attenuated antibody recruitment, confirming EGFR dependence. Strong membrane-associated fluorescence appeared on EGFR-positive HeLa, MDA-MB-231, and A549 cancer cells, while EGFR-negative normal human dermal fibroblasts showed only weak signal. Scanning electron microscopy provided the most vivid evidence: untreated cells displayed smooth membranes, but after incubation with P3, HeLa cells were covered in extensive fibrillar networks, while fibroblasts remained entirely free of such assemblies. In excised tumor tissue sections from mice, P3-treated samples showed pronounced antibody accumulation at tumor cell membranes, whereas the non-assembling control induced minimal recruitment.

Crucially, the recruited antibodies were not merely decorative. When cells coated by P3-recruited anti-DNP antibodies were exposed to complement, the EGFR-positive cancer lines underwent lysis ranging from 20.4 to 39.2 percent, while the EGFR-negative fibroblasts showed essentially no lysis, comparable to vehicle controls. P3 also showed no detectable cytotoxicity toward primary human blood cells at concentrations up to 100 micromolar over 24 hours, suggesting that the immune activation is confined to cells bearing the assembled hapten display rather than being an inherent toxicity of the molecule.

The therapeutic promise carried through to animal models. In HeLa xenograft-bearing mice provided with anti-DNP antibodies, P3 administered every two days at 10 milligrams per kilogram suppressed tumor growth dramatically. After two weeks of treatment, mean tumor volume in the P3 group was 264.1 cubic millimeters, compared with 1264.3 cubic millimeters for vehicle-treated animals and 1003.0 cubic millimeters for those receiving the non-assembling control, corresponding to a tumor growth inhibition rate of 79.1 percent versus 20.7 percent. Safety profiling was equally encouraging: body weights, organ weights, liver enzymes, and hematological parameters remained within normal ranges, histology of major organs revealed no inflammatory infiltration or necrosis, and tumor sections from treated mice showed extensive necrotic regions with nuclear condensation, hallmarks of effective cell killing in vivo.

The authors are candid about a limitation that must be solved before clinical translation: P3’s intrinsic tendency to aggregate in the absence of EGFR binding. They propose that molecular engineering of the self-assembly motif, incorporating hydrophilic or stimulus-responsive elements such as phosphatase-responsive phosphate groups or glucose-derived units, could suppress nonspecific aggregation while preserving receptor-triggered assembly. The modular architecture of the design also invites adaptation: swapping GE11 for ligands targeting other tumor receptors, or DNP for alternative haptens, could generate a family of antibody-recruiting therapeutics tailored to different cancers. By converting a monovalent small molecule into a multivalent immune platform through nothing more than a receptor’s own organizing power, the work establishes a general chemical principle that could reshape how synthetic immunotherapies are built, offering a cheaper, more biocompatible alternative to engineered antibody proteins while harnessing the immune system’s existing arsenal.

Subject of Research: Receptor-triggered peptide self-assembly for multivalent recruitment of endogenous antibodies in cancer immunotherapy

Article Title: Receptor‐Triggered Peptide Self‐Assembly Enables Multivalent Recruitment of Endogenous Antibodies for Cancer Immunotherapy

Article References: Wang, Y., Wu, X., Zhao, C., Han, H., Xie, W., Yuan, D., & Shi, J. (2026). Receptor‐Triggered Peptide Self‐Assembly Enables Multivalent Recruitment of Endogenous Antibodies for Cancer Immunotherapy. Advanced Science, Article e78074. https://doi.org/10.1002/advs.78074

Image Credits: AI Generated

DOI: 10.1002/advs.78074

Keywords: cancer immunotherapy, antibody-recruiting molecules, peptide self-assembly, supramolecular chemistry, EGFR, multivalency, complement-dependent cytotoxicity, dinitrophenyl hapten, GE11 peptide, nanofibers, tumor targeting, Advanced Science

The target in question is C4d, a small fragment of the complement system, the branch of innate immunity that normally helps antibodies destroy microbes and damaged cells. When a therapeutic antibody binds to its antigen on a tumor cell surface, it can trigger the classical complement cascade. Complement component C4 is cleaved, and the active product C4b forms a covalent bond with nearby molecules on the cell membrane. That covalent attachment is crucial, because it means the fragment stays glued to the cell even after the cascade fizzles out. C4b is then progressively inactivated and cleaved by complement regulators, ultimately leaving C4d as the terminal degradation product, still anchored in place.

Here lies the central insight of the study. Tumor cells that survive an antibody assault do so largely because they are protected by complement inhibitors, both membrane-bound proteins such as CD55 and CD59 and soluble regulators circulating in the blood. These inhibitors shut down the cascade before the membrane attack complex, the pore-forming assembly that punches lethal holes in cell membranes, can fully form. But the shutdown process itself leaves C4d behind, covalently deposited on the membrane. In other words, every cell that has been challenged by a complement-activating antibody and lived to tell the tale carries a permanent footprint of that encounter. Cells that were never touched by the first antibody carry no such mark.

This makes C4d a molecular signature of prior antibody exposure, and, more provocatively, a target for a follow-up attack. The research team engineered a candidate anti-C4d antibody as a chimeric human-rabbit construct, a design that combines the specificity of the rabbit-derived binding region with a human antibody framework intended to reduce immunogenicity. Critically, they introduced amino acid substitutions that enhance oligomerization, meaning the antibody molecules cluster more readily once bound to C4d on the cell surface. That clustering matters because complement activation depends on the density of antibody Fc regions; a tightly packed array of Fc domains recruits and assembles the C1 complex far more efficiently than scattered individual antibodies, and therefore ignites a stronger classical pathway response.

To test the concept, the researchers pretreated human lymphoma and breast cancer cells with standard immunotherapeutics and then challenged the surviving cells with the anti-C4d antibody in the presence of normal human serum, which supplies the full repertoire of complement proteins. The results were striking. Applying the anti-C4d antibody significantly increased the killing of lymphoma cells that had previously been treated with the anti-CD20 antibodies rituximab or obinutuzumab, or with the anti-CD38 antibody daratumumab, compared with simply re-treating the cells with the same antibody a second time. The resistant cells, marked by their C4d deposits, became preferential targets of a fresh complement attack.

The effect extended to the hardest cases. The team worked with lymphoma sublines that had been selected for resistance to rituximab, models that represent the clinical nightmare of relapse after anti-CD20 therapy. Even in these sublines, the anti-C4d approach boosted complement-mediated cytotoxicity, suggesting that resistance to the primary antibody does not necessarily abolish the footprint it leaves, nor the ability of a second antibody to exploit it. The strategy also worked in a setting where the first antibody barely activates complement at all: a human breast cancer cell line treated with trastuzumab, the anti-HER2 therapeutic that by itself induced no measurable complement-dependent cytotoxicity in these experiments. Even that weak, sublethal complement activation was enough to deposit C4d, and the anti-C4d antibody converted those sparse deposits into a robust secondary wave of killing.

From a mechanistic standpoint, the approach can be understood as a two-stage amplifier. The first antibody, whether it is rituximab, obinutuzumab, daratumumab or trastuzumab, performs a dual function: it kills some cells directly through complement and immune effector mechanisms, and it tags the survivors with C4d. The second antibody then reads that tag and recruits the complement system again, this time against cells that have already demonstrated they can withstand the first round. Because C4d is covalently bound and resistant to further enzymatic removal, the tag persists on the membrane, giving the second antibody a stable epitope that does not depend on the tumor cell continuing to express the original antigen at high levels, a common escape route in antibody therapy resistance.

The concept also sidesteps several problems that plague conventional second-line strategies. Re-treating patients with the same antibody often fails because antigen expression has dropped or complement regulators have been upregulated, and switching to a different antigen-targeting antibody requires that the new antigen be present and accessible. C4d, by contrast, is deposited as a direct consequence of the first treatment itself, so its presence is essentially guaranteed on cells that experienced complement activation. The approach is therefore not tied to any particular tumor type or antigen; in principle, any complement-activating first-line antibody creates the substrate for the second-line anti-C4d antibody. The authors describe such antibodies as immunotherapeutic amplifiers, capable of converting limited complement activation induced by a primary antibody into a powerful secondary wave of complement-mediated killing.

There are important caveats. This is an in vitro study, conducted with cell lines and normal human serum rather than in patients, and the transition from cell culture to the clinic involves formidable challenges, including the pharmacokinetics of a second antibody, the accessibility of C4d deposits within solid tumors, and the risk of off-target effects on healthy tissues that might carry complement deposits from inflammation. The team also has commercial interests in the technology: Anna Blom and Marcin Okrój are named inventors on a European patent covering antibodies specific for C4d, and a further patent application covers the use of anti-C4d antibodies as second-line immunotherapeutics for patients resistant to first-line therapy. Budka and Okrój receive royalties from a company that commercialized the earlier invention. These disclosures do not diminish the scientific interest of the work, but they signal that the researchers see a clear path toward translation.

Still, the conceptual shift is what makes the study noteworthy. For decades, complement has been viewed mainly as an effector arm that therapeutic antibodies recruit, and resistance has been viewed as a property of the tumor to be overcome with new targets or new drugs. This work reframes the complement fragments left on surviving cells as an opportunity rather than a byproduct, turning the debris of a failed attack into the aiming point for the next one. If the strategy can be validated in animal models and eventually in clinical trials, patients who relapse after rituximab, daratumumab or trastuzumab might one day receive a follow-up antibody that does not need to find a new molecular target at all, because the first treatment has already marked the enemy.

Subject of Research: Targeting the complement C4d fragment to overcome resistance to antibody-based cancer immunotherapy

Article Title: Targeting C4d to overcome resistance to antibody-based immunotherapy: an in vitro study

Article References: Budka, D., Stasiłojć, G., Stasiłojć, M., Kusowska, A., Bieńkowski, M., Bobrowicz, M., Blom, A. M., Winiarska, M., & Okrój, M. (2026). Targeting C4d to overcome resistance to antibody-based immunotherapy: an in vitro study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04567-w

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04567-w

Keywords: C4d, complement system, monoclonal antibodies, immunotherapy resistance, rituximab, obinutuzumab, daratumumab, trastuzumab, lymphoma, breast cancer, complement-dependent cytotoxicity, cancer immunotherapy